Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine : up to 8.4 years of follow-up

• Autor(a) principal: Roteli-Martins, Cecilia M.
• Data de Publicação: 2012
• Outros Autores: Naud, Paulo Sergio Viero, Borba, Paola Colares de, Teixeira, Júlio César, Carvalho, Newton S. de, Zahaf, Toufik, Sanchez, Nervo, Geeraerts, Brecht, Descamps, Dominique
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/115328
• topic: Papillomavirus humano 16; Papillomavirus humano 18; Revisão sistemática; Vacinas contra papillomavirus; Human papillomavirus (HPV); Cervical cancer; HPV-16/18 vaccine; Prophylactic; Long-term immunogenicity; Efficacy

Prophylactic human papillomavirus (HPV) vaccines are now available and vaccination programs are being widely implemented, targeting adolescent girls prior to sexual debut. Since the risk of HPV exposure persists throughout a woman’s sexual life, the duration of protection provided by vaccination is critical to the overall vaccine effectiveness. We report the long-term efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine (Cervarix1) up to 8.4 y after the first vaccine dose. In an initial placebo-controlled study performed in US, Canada and Brazil, women aged 15–25 y with normal cervical cytology, HPV-16/18 seronegative by ELISA, DNA-negative for 14 oncogenic HPV types by PCR, received either the HPV- 16/18 vaccine or placebo (n = 1,113). Subjects were followed up to 6.4 y after the first dose (n = 776). We report an additional 2-y follow-up for women enrolled from the Brazilian centers from the initial study (n = 436). During the current follow-up study (HPV-023, NCT00518336), no new infection or lesions associated with HPV-16/18 occurred in the vaccine group. Vaccine efficacy over the entire follow-up (up to 8.4 y) was 95.1% (84.6, 99.0) for incident infection, 100% (79.8, 100) for 6-mo persistent infection, 100% (56.1, 100) for 12-mo persistent infection and 100% (, 0, 100) for CIN2+ associated with HPV-16/18. All women in the vaccine group remained seropositive to both HPV-16/ 18, with antibody titers for total and neutralizing antibodies remaining several-folds above natural infection levels. The safety profile was clinically acceptable for both vaccine and control groups. This is, to date, the longest follow-up study for a licensed cervical cancer vaccine.